vascular disorder

By Targets:	5-HT Receptor (1) Autophagy (1) Casein Kinase (1) DNA/RNA Synthesis (1) LPL Receptor (1) MAPKAPK2 (MK2) (1) Pim (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Inflammation/Immunology (3) Metabolic Disease (2)

Targets Recommended: VEGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1362

Salvianolic acid B 5+ Cited Publications Lithospermic acid B	Autophagy	Cardiovascular Disease
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.

HY-B1107

Naftidrofuryl oxalate Nafronyl oxalate salt	5-HT Receptor	Cardiovascular Disease
Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.

HY-157746

CTPS1-IN-1	DNA/RNA Synthesis	Inflammation/Immunology Cancer
CTPS1-IN-1 (compound R80) is a CTPS1 inhibitor. CTPS1-IN-1 has the potential to research cancer (such as promoting vascular injury or surgical recovery) and immune system diseases (such as rejection of transplanted cells and tissues, transplant-related diseases or disorders, allergies, and autoimmune diseases) .

HY-W726640

Peraquinsin	MAPKAPK2 (MK2)	Cardiovascular Disease Metabolic Disease
Peraquinsin is a MK2 activator. Peraquinsin can be used for the research of vascular disorder or endothelial barrier disorder. Peraquinsin also is an antihypertensive agent .

HY-135816

CK2/PIM1-IN-1	Casein Kinase Pim	Inflammation/Immunology Cancer
CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC₅₀s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders .

HY-138802

ML089 1 Publications Verification	Others	Metabolic Disease
ML089 is a potent, selective, and orally available phosphomannose isomerase (PMI) inhibitor with an IC₅₀ of 1.3 µM. ML089 can be used for the research of congenital disorder of glycosylation Ia .

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders .

Cat. No.	Product Name

HY-L088

Angiogenesis-Related Compound Library	2,035 compounds
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer). MCE offers a unique collection of 2,035 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Angiogenesis-Related Compound Library

2,035 compounds

Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).

MCE offers a unique collection of 2,035 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1362

Salvianolic acid B 5+ Cited Publications Lithospermic acid B	Cardiovascular Disease Structural Classification Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Source classification Phenols Polyphenols Plants Disease Research Fields	Autophagy
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Natural
Products

Name
Email *

	Sorry, but the email address you supplied was invalid.

vascular disorder

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Natural
Products